Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Tibotec Stories

2013-04-30 08:34:46

-- TMC310911 is Third Product in Growing Ascletis Pipeline of Infectious Disease and Cancer Therapeutics -- HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013 /PRNewswire/ -- Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in...

2012-12-01 05:03:02

New research report “KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen” elaborated by FirstWord has been recently published by Market Publishers Ltd. The study says that the HCV market is expected to have the best growth opportunities over the coming decade in comparison with other Pharma markets. London, UK (PRWEB) November 30, 2012 At present, the hepatitis C (HCV) market is entering a new stage due to the emergence of treatment innovations. The HCV...

2012-06-28 02:28:02

NEUSS, Germany, June 28, 2012 /PRNewswire/ -- Janssen-Cilag GmbH (Janssen) today announced it has completed the acquisition of CorImmun GmbH, a privately held drug development company in Germany, for an undisclosed upfront payment and a contingent future clinical milestone payment. CorImmun's lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical studies to improve heart function by...

2011-12-02 06:30:00

HUDDINGE, Sweden, December 2, 2011 /PRNewswire/ -- Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY). TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection will...

2011-11-17 07:41:00

LAUSANNE, Switzerland, November 17, 2011 /PRNewswire/ -- Funds Will be Used to Commercialize a Fully Automated, Compact Molecular Diagnostics System Designed to Drive the Widespread Adoption of Personalized Medicine and Other Diagnostic Applications Including the Fight Against Infectious Disease Biocartis, a company developing and commercializing compact molecular diagnostic (MDx) systems designed to drive the widespread adoption of...

2011-11-05 08:05:00

SAN FRANCISCO, Nov. 5, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naive patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San...

2011-09-23 06:25:00

TITUSVILLE, New Jersey, September 23, 2011 /PRNewswire/ -- - Third HIV medication submitted by Tibotec - Tibotec Pharmaceuticals (Tibotec), one of the Janssen Pharmaceutical Companies, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of EDURANT(R) (rilpivirine), a 25 mg tablet, as a once-daily treatment in combination with other antiretroviral agents...

2011-07-06 06:00:00

HUDDINGE, Sweden, July 6, 2011 /PRNewswire/ -- Medivir AB (OMX: MVIR), is an emerging research-based specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435 has received "Fast Track" designation by the U.S. Food and Drug Administration ("FDA") for the treatment of chronic hepatitis C (CHC) genotype-1 infection. This is based on TMC435's potential to address unmet medical needs in the...

2011-06-28 07:30:00

CORK, Ireland, June 28, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent. PREZISTA, co-administered with ritonavir...

2011-05-20 13:35:00

TITUSVILLE, N.J., May 20, 2011 /PRNewswire/ -- The US Food and Drug Administration (FDA) today approved EDURANT(TM) (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment-naive). (Photo: http://photos.prnewswire.com/prnh/20110520/SF06258) EDURANT (pronounced ee' dur ant) was developed as TMC278 (rilpivirine) by Tibotec Pharmaceuticals...